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Ventricular assist device support has historically been used
to treat patients with severe refractory heart failure defined by
a specific set of hemodynamic criteria. These have included a
cardiac index of less than 2.0 L · m–2 · min–1, systemic
hypotension with a mean arterial pressure of less than 60 mm
Hg, and elevated cardiac filling pressures (left or right atrial
pressure >20 mm Hg). With experience and wider availabili-
ty of ventricular assist device technology the criteria for
determining the initiation of assist device support have been
somewhat relaxed. Earlier intervention it is hoped may
reduce morbidity. However, most patients currently receiving
ventricular assist device support continue to be hemodynam-
ically compromised and at significant risk for death.
Refractory ventricular arrhythmias develop in a subgroup of
patients with heart failure. This group often have adequate
hemodynamic parameters as long as the arrhythmia is con-
trolled. The inability to predict the onset of ventricular tach-
yarrhythmia and evaluate the likelihood of successful conver-
sion places these patients at a risk for death on a par with that
of those with hemodynamic compromise.
Two men in their 50s with ischemic cardiomyopathy and
long histories of refractory ventricular arrhythmias were eval-
uated and listed for cardiac transplantation at our institution
during 1998. Both patients had received maximum therapy to
control their arrhythmias, including amiodarone, an intracar-
diac defibrillator, a pacemaker, and several attempts at
ectopic focus ablation. While these patients were awaiting
location of a donor heart their conditions deteriorated and
they required continuous hospitalization. Within a short peri-
od their congestive heart failure had improved in response to
conventional medical therapy including low-dose inotropic
support. During the next 3 to 6 weeks their conditions wors-
ened, necessitating increased medications. In addition, more
frequent and refractory episodes of ventricular tachycardia
developed. In the hope of stabilizing and possibly controlling
the ventricular tachycardia until transplantation could be
accomplished it was decided to place ventricular assist devices.
Before ventricular assist device placement both patients
had cardiac indexes greater than 2.2 L · m–2 · min–1 and sys-
temic mean arterial pressures greater than 60 mm Hg.
Pulmonary capillary wedge and pulmonary arterial pressures
were elevated. The serum creatinine concentrations were 1.3
mg/dL and 1.7 mg/dL. The patients were ambulatory but con-
fined to the intensive care unit. Without the arrhythmia prob-
lems these patients would not have been considered for ven-
tricular assist device placement at that time. The implants
were placed electively during periods of hemodynamic sta-
bility. Both patients had Thoratec left ventricular assist
devices (Thoratec Laboratories Corporation, Pleasanton,
Calif) implanted with left ventricular apex to aortic cannula-
tion. The implantation procedures were uneventful, with both
patients requiring small doses of inotropic drugs to augment
right ventricular function.
During the first 12 hours after the operation ventricular
tachycardia occurred intermittently; however, these episodes
were short and left ventricular assist device flow and other
hemodynamic parameters remained stable. Refractory ven-
tricular tachycardia at the rate of 150 to 160 beats/min devel-
oped in the second patient approximately 14 hours after the
operation. This continued for 12 hours and was finally con-
verted with a combination of drugs and pacemaker manipula-
tions. During this 12-hour period the left ventricular assist
device output, arterial pressure, filling pressures, urinary out-
put, and other hemodynamic parameters remained stable. The
patient was awake and appropriate.
On the seventh postoperative day for first patient and the
10th postoperative day for the second patient each had con-
version to ventricular tachycardia at rates between 150 to 170
beats/min. Both patients had been progressing well and were
in the step-down unit. They remained in stable condition with
left ventricular assist device flows in excess of 5 L/min. The
first patient was transferred to the intensive care unit because
he had some angina and shortness of breath with his arrhyth-
mia. He remained in ventricular tachycardia for 8 days, after
which time he required radiofrequency ablation of the ectopic
focus. He had conversion to a ventricularly paced rhythm at a
rate of 90 beats/min and remained in this rhythm for 2 months
until he received his transplant.
The other patient had several episodes of ventricular tachy-
cardia, ranging in duration from a few hours to several days,
before a combination of amiodarone and mexiletine along
with pacemaker manipulations produced a stable rhythm. He
remained ventricularly paced at a rate of 100 beats/min until
cardiac transplantation was successfully accomplished 6
weeks later.
In these cases the indications to proceed with ventricular
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assist device support were similar. The incidence and severi-
ty of the ventricular tachycardia were increasing. Because the
amount of time necessary to locate a donor heart was
unknown, it was thought wise to proceed with left ventricular
assist device placement in the hope of stabilizing the patient’s
condition during the waiting period. In both cases the ven-
tricular arrhythmias actually worsened after left ventricular
assist device implantation. Fortunately, the rates of the ven-
tricular tachycardias were relatively slow (150-170
beats/min) and the rhythm never deteriorated to ventricular
fibrillation. For this reason, despite the fact that the arrhyth-
mia itself worsened, the patients remained in hemodynami-
cally stable condition and had improvement while receiving
left ventricular assist device support. Eventually a combina-
tion of conventional and mechanical support therapies sub-
dued the tachyarrhythmias and provided a period of stabiliza-
tion during which both patients could be rehabilitated for
transplantation. One patient was able to undergo successful
ablation because of the stability provided by the left ventric-
ular assist device. Before left ventricular assist device place-
ment he would not have been able to tolerate this procedure.
The other patient was considered for ablation; however, we
were able to control his arrhythmia pharmacologically.
Finally, both these cases were far more complicated than
we had anticipated. As previous experience has taught us,
most patients with left ventricular assist devices tolerate ven-
tricular tachycardia well.1-3 Like others we remain concerned
about preserving right ventricular function in a patient with
only a left ventricular assist device who has prolonged
episodes of ventricular tachycardia. One of the dangers to
avoid is overly aggressive treatment of a patient whose con-
dition is hemodynamically stable. Some would suggest that it
is advisable to place biventricular assist devices in any patient
who is at risk for development of ventricular tachyarrhyth-
mia. In the future we will be more inclined to use biventricu-
lar assist devices.4
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